How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/staphylococcus-epidermidis-skin-and-skin-structure-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Staphylococcus Epidermidis Skin and Skin Structure Infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Staphylococcus Epidermidis Skin and Skin Structure Infection (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Staphylococcus Epidermidis Skin and Skin Structure Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Cefaprin	cefapirin	Bristol-Myers Squibb	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Vancocin	vancomycin	ANI Pharmaceuticals		Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Ciprofloxacine	Ciprofloxacine	Poitiers University Hospital		DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 6 drugs in Staphylococcus Epidermidis Skin and Skin Structure Infection
Bristol-Myers Squibb · 2 drugs in Staphylococcus Epidermidis Skin and Skin Structure Infection
ANI Pharmaceuticals · 1 drug in Staphylococcus Epidermidis Skin and Skin Structure Infection
Assistance Publique - Hôpitaux de Paris · 1 drug in Staphylococcus Epidermidis Skin and Skin Structure Infection
Bayer AG · 1 drug in Staphylococcus Epidermidis Skin and Skin Structure Infection
Poitiers University Hospital · 1 drug in Staphylococcus Epidermidis Skin and Skin Structure Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Staphylococcus Epidermidis Skin and Skin Structure Infection:

Cite this brief

Drug Landscape (2026). Staphylococcus Epidermidis Skin and Skin Structure Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/staphylococcus-epidermidis-skin-and-skin-structure-infection. Accessed 2026-06-10.

Staphylococcus Epidermidis Skin and Skin Structure Infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing